HHS awards $37.6M contract to 4J Therapeutics for antiviral technology platform development and Phase 1A study

Contract Overview

Contract Amount: $37,589,802 ($37.6M)

Contractor: 4J Therapeutics Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2024-09-30

End Date: 2032-03-31

Contract Duration: 2,739 days

Daily Burn Rate: $13.7K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND

Place of Performance

Location: PALO ALTO, SANTA CLARA County, CALIFORNIA, 94304

State: California Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $37.6 million to 4J THERAPEUTICS INC for work described as: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND Key points: 1. Contract focuses on advancing a programmable antiviral technology platform through preclinical and early-stage human trials. 2. The award represents a significant investment in novel antiviral research and development. 3. Performance period extends over 7 years, indicating a long-term commitment to platform maturation. 4. The contract type (Cost Plus Fixed Fee) suggests potential for cost overruns but allows flexibility in R&D. 5. This award aligns with national priorities for pandemic preparedness and response. 6. The geographic focus is California, potentially leveraging local biotech expertise.

Value Assessment

Rating: fair

The contract value of $37.6 million over approximately 7.5 years for R&D in biotechnology is within a reasonable range for developing a novel therapeutic platform and conducting a Phase 1A study. However, without specific benchmarks for this particular technology or comparable early-stage antiviral development contracts, a precise value-for-money assessment is challenging. The Cost Plus Fixed Fee (CPFF) structure means the government pays the actual costs plus a negotiated fee, which can lead to higher final costs than fixed-price contracts if development proves more complex or expensive than initially anticipated. Benchmarking against similar early-stage R&D efforts in the biotech sector would be necessary for a more definitive assessment.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple interested parties had the opportunity to bid. This process is designed to foster a competitive environment, potentially leading to better pricing and innovative solutions. The number of bidders is not specified, but the full and open nature suggests a robust selection process. This approach is generally favored for ensuring the government receives the best value by considering a wide range of qualified contractors.

Taxpayer Impact: Full and open competition is beneficial for taxpayers as it increases the likelihood of securing competitive pricing and encourages innovation from a broader base of potential suppliers, ultimately aiming for more efficient use of public funds.

Public Impact

The primary beneficiaries are public health, through the potential development of new antiviral treatments. The contract aims to deliver a preclinical package and conduct a Phase 1A study for LNA14. The geographic impact is centered in California, where the contractor is located. Workforce implications include potential job creation in biotechnology research and development within the contractor's organization.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Cost Plus Fixed Fee (CPFF) contracts can lead to higher final costs if development challenges arise.
The long performance period (over 7 years) increases the risk of scope creep or shifts in research priorities.
Early-stage R&D is inherently risky, with no guarantee of successful therapeutic development.
Reliance on a single technology platform (LNA14) carries inherent risks if it proves ineffective or unsafe.

Positive Signals

Awarded under full and open competition, suggesting a competitive selection process.
Focus on a programmable antiviral technology platform addresses a critical public health need.
The Phase 1A study is a crucial step in validating the safety and efficacy of the technology in humans.
The long-term nature of the contract allows for sustained development and potential breakthroughs.

Sector Analysis

The biotechnology sector is characterized by high R&D investment and significant innovation potential. This contract falls within the 'Research and Development in Biotechnology' category, focusing on antiviral technologies. The market for antiviral therapeutics is substantial, driven by the ongoing threat of infectious diseases and pandemics. Government investment in this area is crucial for developing countermeasures that the private sector might not pursue due to high risk and long development timelines. Comparable spending benchmarks would typically involve looking at other government-funded early-stage drug development programs or grants awarded by agencies like NIH or BARDA.

Small Business Impact

This contract does not appear to involve a small business set-aside, as the contractor, 4J Therapeutics Inc., is likely a mid-to-large sized entity given the contract value and scope. There is no explicit mention of subcontracting requirements for small businesses. Therefore, the direct impact on the small business ecosystem from this specific award is likely minimal, although the contractor may engage small businesses as vendors or suppliers in their supply chain.

Oversight & Accountability

Oversight for this contract will likely be managed by the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), which is responsible for public health emergencies. Accountability measures will be tied to the achievement of milestones outlined in the Cost Plus Fixed Fee contract, including the delivery of the preclinical package and the successful completion of the Phase 1A study. Transparency will be facilitated through regular reporting requirements from the contractor and potential public disclosures of study results, subject to proprietary and regulatory considerations. Inspector General jurisdiction would apply to any allegations of fraud, waste, or abuse related to the contract funds.

Related Government Programs

Biotechnology Research and Development
Antiviral Drug Development
Pandemic Preparedness Programs
Phase 1 Clinical Trials
Therapeutic Platform Development

Risk Flags

Potential for cost overruns due to CPFF contract type.
Inherent risks in early-stage R&D with no guarantee of success.
Long performance period may increase risk of scope changes or obsolescence.
Dependence on a single technology platform (LNA14).

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $37.6 million to 4J THERAPEUTICS INC. THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND

Who is the contractor on this award?

The obligated recipient is 4J THERAPEUTICS INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $37.6 million.

What is the period of performance?

Start: 2024-09-30. End: 2032-03-31.

What is the specific nature of the 'programmable antiviral technology platform' and LNA14?

The provided data does not detail the specific scientific mechanisms of the 'programmable antiviral technology platform' or LNA14. However, 'programmable' suggests a technology that can be adapted or modified to target different viruses or strains. LNA14 is likely a specific drug candidate or therapeutic agent developed using this platform. The contract's objective is to assemble the preclinical package (e.g., laboratory and animal studies) and conduct a Phase 1A study (initial safety and dosage testing in a small group of healthy humans) to demonstrate the platform's versatility and the candidate's efficacy and safety. Further details would typically be found in the technical proposal or scientific literature associated with 4J Therapeutics.

How does the $37.6 million contract value compare to similar R&D efforts in antiviral development?

Assessing the $37.6 million contract value requires context regarding the specific stage of development and the scope of work. Early-stage R&D, especially for novel platforms and initial human trials (Phase 1A), can vary significantly in cost. Contracts for preclinical packages and Phase 1 studies can range from a few million to tens of millions of dollars, depending on the complexity, the number of studies required, and the specific therapeutic area. Given that this contract covers both preclinical development and a Phase 1A study over a substantial period (over 7 years), $37.6 million appears to be within a plausible range for a government-funded initiative aiming to advance a promising technology. However, direct comparisons are difficult without knowing the specific targets, the novelty of the platform, and the detailed work breakdown structure.

What are the key performance indicators (KPIs) for this contract and how will success be measured?

The key performance indicators (KPIs) for this contract are not explicitly detailed in the provided summary. However, based on the contract's objective, success will likely be measured by the successful completion of specific milestones. These would include the timely delivery and acceptance of the preclinical data package, demonstrating the safety and efficacy of LNA14 in relevant models. For the Phase 1A study, KPIs would involve meeting enrollment targets, collecting comprehensive safety and pharmacokinetic data, determining appropriate dosage ranges, and demonstrating an acceptable safety profile in healthy human subjects. Adherence to the contract schedule, budget, and quality standards will also be critical performance measures.

What is 4J Therapeutics Inc.'s track record in developing and commercializing antiviral therapies?

Information regarding 4J Therapeutics Inc.'s specific track record in developing and commercializing antiviral therapies is not provided in the data summary. To assess their capabilities, one would need to research the company's history, previous government contracts, publications, patents, and any existing product pipeline or approvals. Their success in prior R&D endeavors, particularly in areas related to biotechnology and infectious diseases, would be crucial indicators of their ability to execute this contract effectively. Without this external information, it's impossible to evaluate their past performance in this specific domain.

What are the potential risks associated with the Cost Plus Fixed Fee (CPFF) contract type for this project?

The Cost Plus Fixed Fee (CPFF) contract type, while offering flexibility for R&D projects with uncertain technical paths, carries inherent risks for the government. The primary risk is that the final cost could exceed initial estimates, as the government reimburses the contractor for all allowable costs incurred, plus a predetermined fixed fee. If the project encounters unforeseen technical challenges, requires more resources than anticipated, or experiences delays, the total expenditure can increase significantly. This structure provides less cost certainty compared to fixed-price contracts. For this project, the CPFF structure means that if the development of the LNA14 platform or the Phase 1A study proves more complex or time-consuming than planned, the government will bear the additional cost, although the contractor's profit (the fixed fee) remains constant.

How does this contract align with the Department of Health and Human Services' broader mission and strategic goals?

This contract directly aligns with the Department of Health and Human Services' (HHS) broader mission, particularly its focus on public health preparedness and response to emerging infectious diseases. The Office of Assistant Secretary for Preparedness and Response (ASPR) specifically works to prepare the nation for the health consequences of major disasters and emergencies, including pandemics. By funding the development and early-stage testing of novel antiviral technologies like LNA14, HHS is investing in critical countermeasures that could be vital during future public health crises. This initiative supports strategic goals related to advancing medical countermeasures, strengthening the nation's biodefense capabilities, and ensuring the availability of effective treatments against viral threats.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: BAA-23-100-SOL-00004

Offers Received: 1

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 965 CLARK WAY, PALO ALTO, CA, 94304

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Self-Certified Small Disadvantaged Business, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $330,136,249

Exercised Options: $37,589,802

Current Obligation: $37,589,802

Actual Outlays: $5,282,945

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline